YAP1 Expression in SCLC Defines a Distinct Subtype With T-cell–Inflamed Phenotype
Open Access
- 25 November 2020
- journal article
- research article
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 16 (3) , 464-476
Abstract
No abstract availableKeywords
Funding Information
- Merck
- National Institutes of Health (P50CA217691, U01CA217875)
- Novartis (CLDK378AUS39T)
- U.S. Department of War (LC150291)
- Roche
- National Cancer Institute (P30CA138292)
- Winship Cancer Institute
- AstraZeneca
- Bristol-Myers Squibb
This publication has 26 references indexed in Scilit:
- ASCL1 and NEUROD1 Reveal Heterogeneity in Pulmonary Neuroendocrine Tumors and Regulate Distinct Genetic ProgramsCell Reports, 2016
- Outlier analysis of functional genomic profiles enriches for oncology targets and enables precision medicineBMC Genomics, 2016
- Comprehensive genomic profiles of small cell lung cancerNature, 2015
- A Translational, Pharmacodynamic, and Pharmacokinetic Phase IB Clinical Study of Everolimus in Resectable Non–Small Cell Lung CancerClinical Cancer Research, 2015
- DNA methylation in small cell lung cancer defines distinct disease subtypes and correlates with high expression of EZH2Oncogene, 2015
- The immune contexture of primary and metastatic human tumoursCurrent Opinion in Immunology, 2014
- Integrative genome analyses identify key somatic driver mutations of small-cell lung cancerNature Genetics, 2012
- Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancerNature Genetics, 2012
- The immune contexture in human tumours: impact on clinical outcomeNature Reviews Cancer, 2012
- Long-Term Survival for Patients With Non–Small-Cell Lung Cancer With Intratumoral Lymphoid StructuresJournal of Clinical Oncology, 2008